TBL1XR1 and acute promyelocytic leukemia: In a mouse model with TBLR1-RARA expression, TBLR1-RARA performed as an oncogene to trigger APL-like disease and HDAC inhibitors rather than ATRA or As2O3 conferred survival advantage against TBLR1-RARA expression mice (25).